Education
About Us
Working with TipRanks
Follow Us
Enlivex Therapeutics Ltd (ENLV)
NASDAQ:ENLV
ENLV Analyst Ratings
Moderate Buy
1 Buy
1 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
ENLV Stock 12 Month Forecast
Average Price Target
$7.00
▲(629.17% Upside)
| Highest Price Target$7.00 | Average Price Target$7.00 | Lowest Price Target$7.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
D. Boral Capital
―
Hold
―
Downgraded
11/24/25
H.C. Wainwright
$7
Buy
629.17%
Upside
Reiterated
09/15/25
Enlivex's Strategic Advancements and Patent Protection Drive Buy Rating for Osteoarthritis TreatmentValuation and Risks. We value Enlivex using a discounted cash flow (DCF)-based methodology. This employs a 12% discount rate, 1% terminal growth rate and 25% effective tax rate. Conservatively, we currently only model Allocetra sales in sepsis and osteoarthritis, although the platform may have applicability in other indications as well. We derive a total firm value of $240M, or a price objective of $7 per share assuming 34.3M fully-diluted shares outstanding as of mid-2026.
Analyst Type
Any
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
D. Boral Capital
―
Hold
―
Downgraded
11/24/25
H.C. Wainwright
$7
Buy
629.17%
Upside
Reiterated
09/15/25
Enlivex's Strategic Advancements and Patent Protection Drive Buy Rating for Osteoarthritis TreatmentValuation and Risks. We value Enlivex using a discounted cash flow (DCF)-based methodology. This employs a 12% discount rate, 1% terminal growth rate and 25% effective tax rate. Conservatively, we currently only model Allocetra sales in sepsis and osteoarthritis, although the platform may have applicability in other indications as well. We derive a total firm value of $240M, or a price objective of $7 per share assuming 34.3M fully-diluted shares outstanding as of mid-2026.
Best Analysts Covering Enlivex
1 Month
xxx
Success Rate
2/5 ratings generated profit
Average Return
+2.46%
reiterated a xxx
rating 3 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 40.00% of your transactions generating a profit, with an average return of +2.46% per trade.
3 Months
xxx
Success Rate
3/5 ratings generated profit
Average Return
+2.40%
reiterated a xxx
rating 3 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 60.00% of your transactions generating a profit, with an average return of +2.40% per trade.
1 Year
Success Rate
0/5 ratings generated profit
Average Return
-13.04%
reiterated a buy rating 3 months ago
Copying Ram Selvaraju's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -13.04% per trade.
2 Years
xxx
Success Rate
0/5 ratings generated profit
Average Return
-13.96%
reiterated a xxx
rating 3 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 0.00% of your transactions generating a profit, with an average return of -13.96% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
ENLV Analyst Recommendation Trends
Rating
Jan 25
Mar 25
Apr 25
Sep 25
Nov 25
Strong Buy
0
1
2
4
3
Buy
0
0
0
0
0
Hold
0
0
0
0
1
Sell
7
4
3
0
0
Strong Sell
0
0
0
0
0
total
7
5
5
4
4
Each month's total comprises the sum of three months' worth of ratings.
ENLV Financial Forecast
ENLV Stock Forecast FAQ
What is ENLV’s average 12-month price target, according to analysts?
Based on analyst ratings, Enlivex Therapeutics Ltd’s 12-month average price target is 7.00.
What is ENLV’s upside potential, based on the analysts’ average price target?
Enlivex Therapeutics Ltd has 629.17% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is ENLV a Buy, Sell or Hold?
Enlivex Therapeutics Ltd has a consensus rating of Moderate Buy which is based on 1 buy ratings, 1 hold ratings and 0 sell ratings.
What is Enlivex Therapeutics Ltd’s price target?
The average price target for Enlivex Therapeutics Ltd is 7.00. This is based on 2 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $7.00 ,the lowest forecast is $7.00. The average price target represents 629.17% Increase from the current price of $0.96.
The highest analyst price target is $7.00 ,the lowest forecast is $7.00. The average price target represents 629.17% Increase from the current price of $0.96.
What do analysts say about Enlivex Therapeutics Ltd?
Enlivex Therapeutics Ltd’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 2 Wall Streets Analysts.
How can I buy shares of ENLV?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.